Champions Oncology, Inc. — Form 10-Q Summary
Business context and reporting period. The unaudited report covers the three and nine months ended January 31, 2015, the company’s fiscal third quarter. Champions Oncology develops TumorGraft-based oncology services through Personalized Oncology Solutions (POS) for physicians and patients and Translational Oncology Solutions (TOS) for pharmaceutical and biotechnology companies. Amounts below are in thousands of dollars, except per-share data.
Financial results and position
| Metric | Three months ended Jan. 31, 2015 | Three months ended Jan. 31, 2014 | Nine months ended Jan. 31, 2015 | Nine months ended Jan. 31, 2014 |
|---|---|---|---|---|
| Revenue | $1,829 | $3,690 | $5,622 | $9,092 |
| Operating loss | $(3,419) | $(1,408) | $(10,834) | $(3,882) |
| Net loss | $(2,816) | $(574) | $(9,463) | $(5,134) |
| Basic loss per share | $(0.04) | $(0.01) | $(0.14) | $(0.08) |
- Revenue and margins: Third-quarter POS revenue was $453, with gross margin of (48.8%); TOS revenue was $1,376, with gross margin of 5.5%. For the nine months, POS and TOS gross margins were (75.9%) and 26.3%, respectively. The filing attributes weak POS margin to lower revenue against fixed costs, and weak quarterly TOS margin to new studies whose revenue would be recognized upon completion.
- Cash flow: The cash flow statement reports $7,622 of cash used in operations and $84 used in investing during the nine months. Financing provided $1,997, primarily from executive notes. Cash declined $5,709 to $182.
- Balance sheet at Jan. 31, 2015: Current assets were $1,532 and current liabilities $6,269, corresponding to negative working capital of approximately $4.7 million. Total liabilities were $6,977; stockholders’ deficit was $4,144. Cash was $182, accounts receivable $1,092, and deferred revenue $2,309.
- Debt and liquidity: Current liabilities included $2,000 of convertible notes issued to the CEO and president, each bearing 12% annual interest and originally due after 90 days. The notes were later extended to April 1, 2015 and converted into equity in connection with the subsequent financing.
- Noncash item: The company recorded $1,401 of nine-month income from the change in fair value of warrant liabilities; the filing says this revaluation did not affect cash. Warrant liability was $610 at period-end, down from $2,011 at April 30, 2014.
Material changes versus the prior comparable period
- Revenue fell 50.4% in the quarter and 38.2% for the nine months. POS revenue declined 23.2% and 32.1%, respectively; TOS declined 55.6% and 39.7%.
- The TOS quarterly comparison was affected by a $1.9 million licensing agreement signed in the prior-year third quarter, with $1.4 million recognized immediately then.
- Nine-month operating expenses increased 26.8% to $16,456. Research and development rose 132.8% to $3,757, reflecting investment in TumorBank expansion and genomic characterization; sales and marketing rose 54.6% to $3,340, mainly from expanding TOS business development.
- Nine-month operating loss widened to $10,834 from $3,882, and net loss widened to $9,463 from $5,134. General and administrative expense declined 11.9% for the nine months, which management attributed in part to cost-saving measures.
- Cash used in operations increased year over year. The cash flow statement gives prior-period operating cash use of $3,558, but the MD&A states $2.5 million; the filing text does not reconcile this difference.
Outlook, risks, contingencies, and unusual items
- Management said on March 17, 2015 that it believed the company had sufficient cash to continue as a going concern for at least 12 months, following a March 11 securities purchase agreement for aggregate proceeds of $14 million. The financing involved common-stock-and-warrant units priced at $0.40; the filing does not state net proceeds in the provided text.
- The financing and related amendments triggered additional share and warrant issuances under earlier agreements’ antidilution provisions. Investors also received specified put, participation, and registration rights. These terms may affect future dilution and liquidity.
- Management planned to continue expanding the TumorGraft platform and POS and TOS programs, but the filing provides no quantified revenue, earnings, or cash-flow guidance.
- Potential registration-default penalties under prior agreements were not accrued because management did not consider them probable. The filing reports no known legal proceedings and no material off-balance-sheet debt or similar obligations.
- Management identified estimates involving receivables, revenue recognition, goodwill, deferred tax assets, stock compensation, and warrant valuation as significant. Warrant valuation uses Level 3 inputs. Management reported disclosure controls were effective and no material changes to internal control over financial reporting during the period.
Important facts for investors to verify
- Confirm the closing, net proceeds, and use of proceeds of the $14 million March 2015 financing, along with the resulting share count, warrant terms, and dilution.
- Assess whether operating cash burn and negative working capital improved after the financing, and whether management’s 12-month liquidity assessment remains supported.
- Track POS commercial implant volumes and revenue, TOS study completion and revenue recognition, and whether segment gross margins recover.
- Reconcile the prior-year operating cash-use figures ($3,558 in the cash flow statement versus $2.5 million in MD&A).
- Review the related-party convertible-note conversion, investor put and registration rights, and any potential registration penalties or other financing obligations.